Edition:
India

Horizon Therapeutics PLC (HZNP.OQ)

HZNP.OQ on NASDAQ Stock Exchange Global Select Market

23.64USD
1:30am IST
Change (% chg)

$-0.24 (-1.01%)
Prev Close
$23.88
Open
$23.88
Day's High
$24.17
Day's Low
$23.58
Volume
414,530
Avg. Vol
611,042
52-wk High
$29.44
52-wk Low
$15.92

Latest Key Developments (Source: Significant Developments)

Nuvo Pharmaceuticals Says U.S. Court Of Appeals Reverses District Court's Decision On Some Vimovo Patents
Wednesday, 15 May 2019 

May 15 (Reuters) - Nuvo Pharmaceuticals Inc ::NUVO PHARMACEUTICALS™ ANNOUNCES THAT U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT REVERSES DISTRICT COURT'S DECISION RELATED TO CERTAIN VIMOVO PATENTS.NUVO PHARMACEUTICALS INC - RULING REVERSES DECISION MADE ON JULY 10, 2017 INVOLVING PATENTS U.S. PATENT NOS. 6,926,907 AND 8,557,285.NUVO PHARMACEUTICALS INC - DECISION DOES NOT IMPACT CO'S EX-U.S. PATENTS OR RELATED ROYALTY STREAMS FOR VIMOVO.  Full Article

Horizon Pharma - Received Civil Investigative Demand From United States Department Of Justice
Wednesday, 6 Mar 2019 

March 5 (Reuters) - Horizon Pharma PLC ::HORIZON PHARMA - RECEIVED CIVIL INVESTIGATIVE DEMAND FROM UNITED STATES DEPARTMENT OF JUSTICE.HORIZON PHARMA - CID FROM U.S. DOJ IS REGARDING ASSERTIONS THAT CERTAIN OF PAYMENTS TO PBMS WERE POTENTIALLY IN VIOLATION OF ANTI-KICKBACK STATUTE.HORIZON PHARMA - CID FROM U.S. DOJ REQUESTS CERTAIN DOCUMENTS AND INFORMATION RELATED TO PAYMENTS TO PBMS.HORIZON PHARMA - CID FROM U.S. DOJ REQUESTS CERTAIN DOCUMENTS RELATED TO PRICING, PATIENT ASSISTANCE PROGRAM REGARDING DUEXIS, VIMOVO & PENNSAID 2%.HORIZON PHARMA - INTEND TO COOPERATE WITH U.S. DOJ INVESTIGATION.HORIZON PHARMA - BELIEVE THAT PAYMENTS AND PROGRAMS ARE COMPLIANT WITH ANTI-KICKBACK STATUTE.  Full Article

Horizon Pharma Says FY 2019 Net Sales Guidance Of $1.23 Bln-$1.25 Bln
Wednesday, 27 Feb 2019 

Feb 28 (Reuters) - Horizon Pharma PLC ::FOURTH-QUARTER 2018 NET SALES INCREASED 30 PERCENT TO $355.5 MILLION.2018 GAAP NET INCOME OF $87.6 MILLION.FULL-YEAR 2019 NET SALES GUIDANCE OF $1.23 BILLION TO $1.25 BILLION.FULL-YEAR 2019 ADJUSTED EBITDA GUIDANCE OF $440 MILLION TO $455 MILLION.ON A GAAP BASIS IN Q4 OF 2018, DILUTED EARNINGS PER SHARE WERE $0.50.Q4 EARNINGS PER SHARE VIEW $0.54, REVENUE VIEW $334.2 MILLION -- REFINITIV IBES DATA.FY REVENUE VIEW $1.24 BILLION -- REFINITIV IBES DATA.  Full Article

Horizon Pharma Plc Announces Agreement To License Pre-Clinical Uricase Derivative From Medimmune
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Horizon Pharma Plc ::HORIZON PHARMA PLC ANNOUNCES AGREEMENT TO LICENSE PRE-CLINICAL URICASE DERIVATIVE (MEDI4945) FROM MEDIMMUNE.HORIZON PHARMA PLC - WILL PROVIDE MEDIMMUNE AN UPFRONT CASH PAYMENT AND FUTURE PAYMENTS CONTINGENT ON MEDI4945 DEVELOPMENT AND SALES MILESTONES.  Full Article

Horizon Pharma Sees Krystexxa FY 2018 Sales Up More Than 50 Percent
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Horizon Pharma Plc ::HORIZON PHARMA SEES KRYSTEXXA FY 2018 SALES UP MORE THAN 50 PERCENT.HORIZON PHARMA PLC - INCREASING ITS ESTIMATED PEAK ANNUAL NET SALES EXPECTATIONS FOR EACH MEDICINE TO MORE THAN $750 MILLION.HORIZON PHARMA PLC INCREASES PEAK NET SALES GUIDANCE FOR KEY GROWTH DRIVERS AND ANNOUNCES RHEUMATOLOGY AND ORPHAN PIPELINE DEVELOPMENTS.  Full Article

Horizon Pharma Announces FDA Approval to Expand the Indication for Procysbi
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Horizon Pharma Plc ::HORIZON PHARMA PLC ANNOUNCES FDA APPROVAL TO EXPAND THE INDICATION FOR PROCYSBI® (CYSTEAMINE BITARTRATE) DELAYED-RELEASE CAPSULES TO INCLUDE CHILDREN ONE YEAR OF AGE AND OLDER LIVING WITH NEPHROPATHIC CYSTINOSIS.  Full Article

Horizon Pharma reports Q3 Non-GAAP earnings per share $0.26
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Horizon Pharma Plc : :Horizon Pharma plc announces third-quarter and year-to-date 2017 results.Q3 sales $271.6 million versus I/B/E/S view $259.7 million.Q3 earnings per share view $0.22 -- Thomson Reuters I/B/E/S.Sees FY 2017 sales $1.03 billion to $1.05 billion.Q3 GAAP loss per share $0.39.Q3 Non-GAAP earnings per share $0.26.Horizon Pharma plc says sees FY 2017 ‍adjusted EBITDA guidance range of $350 million to $375 million from $340 million to $375 million.Horizon Pharma says sees Krystexxa 2018 net sales up more than 50 percent​.  Full Article

Horizon pharma plc announces Q3 non-gaap earnings per share $0.26
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Horizon Pharma PLC :Horizon Pharma PLC announces third-quarter and year-to-date 2017 results.Q3 Non-GAAP earnings per share $0.26.Q3 sales $271.6 million versus I/B/E/S view $259.7 million.Q3 earnings per share view $0.22 -- Thomson Reuters I/B/E/S.Sees FY 2018 sales up more than 50 percent.Sees FY 2017 sales $1.03 billion to $1.05 billion.Q3 gaap loss per share $0.39.Horizon Pharma PLC - sees FY 2017 ‍adjusted EBITDA guidance range of $350 million to $375 million from $340 million to $375 million​.  Full Article

Horizon Pharma says first patient enrolled in confirmatory Phase 3 clinical trial evaluating Teprotumumab
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Horizon Pharma Plc :Horizon Pharma Plc announces first patient enrolled in confirmatory Phase 3 clinical trial evaluating Teprotumumab for the treatment of moderate-to-severe active thyroid eye disease.  Full Article

Horizon Pharma borrows $845.8 mln principal amount of loans
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Horizon Pharma Plc -:Horizon Pharma - co, units borrowed $845.8 million principal amount of loans pursuant to amendment to credit agreement dated as of may 7, 2015-sec filing​.  Full Article

Recordati to seek Canadian approval for kidney disease drug

TORONTO Italy's Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which treats a rare kidney disease, in a potential blow to Horizon Pharma,, which makes the only drug approved for treatment in Canada.